Regeneron Pharmaceuticals (REGN) Receivables - Other (2009 - 2020)

Regeneron Pharmaceuticals' Receivables - Other history runs 12 years deep, the most recent figure standing at $460.8 million for Q3 2020.

• In Q3 2020, Receivables - Other rose 33.41% year-over-year to $460.8 million; the TTM figure through Sep 2020 stood at $460.8 million (up 33.41% YoY), while the FY2019 annual figure was $260.6 million, up 15.11% from the prior year.
• Receivables - Other was $460.8 million for Q3 2020 at Regeneron Pharmaceuticals, up from $389.2 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $468.3 million in Q1 2020 to a low of $93.0 million in Q4 2016.
• Historically, Receivables - Other has averaged $249.8 million across 5 years, with a median of $226.4 million in 2018.
• The sharpest annual moves came in 2016 and 2017: Receivables - Other sank 39.28% in 2016, then surged 108.3% in 2017.
• A 5-year view of Receivables - Other shows it stood at $93.0 million in 2016, then soared by 108.3% to $193.7 million in 2017, then climbed by 16.88% to $226.4 million in 2018, then advanced by 15.11% to $260.6 million in 2019, then soared by 76.82% to $460.8 million in 2020.
• The last three Receivables - Other figures came in at $460.8 million (Q3 2020), $389.2 million (Q2 2020), and $468.3 million (Q1 2020), per Business Quant data.